Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506181 | 0.85 | ATM (0.37) | VCPMAPTPKMMAPK1ATM | |
| SCHEMBL4577560 | 0.82 | ATM (0.36) | ATMTDP1ALDH1A1HIF1AVCAM1 | |
| SCHEMBL1822058 | 0.78 | ALDH1A1 (0.46) | MAPTPKMMAPK1ATMTDP1 | |
| SCHEMBL27684781 | 0.77 | ALDH1A1 (0.36) | MAPTMAPK1ATMTDP1ALDH1A1 | |
| SCHEMBL4902091 | 0.77 | CA12 (0.34) | MAPTMAPK1TDP1ALDH1A1HIF1A | |
| SCHEMBL9304210 | 0.74 | ALDH1A1 (0.33) | MAPTMAPK1ATMTDP1ALDH1A1 | |
| SCHEMBL28774035 | 0.73 | ALDH1A1 (0.36) | MAPTMAPK1ATMTDP1ALDH1A1 | |
| SCHEMBL21808035 | 0.73 | HTT (0.38) | MAPTPKMTDP1ALDH1A1CYP3A4 | |
| SCHEMBL27818989 | 0.73 | ALDH1A1 (0.33) | TDP1ALDH1A1HIF1ACYP3A4 | |
| SCHEMBL28738082 | 0.69 | HTT (0.38) | MAPTPKMTDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208827-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | VCP 2468/4885MAPT 4399/4885PKM 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.